The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US, and Naresh Bumma, The Ohio State University, Columbus, US. We asked, How to select maintenance therapies post-autologous stem cell transplant (ASCT) for p

Should risk-adapted MM treatment be informed by age or frailty status?

Sep 12th, 2023 4m 33s

The Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Should risk-adapted MM treatment be informed by age or frailty status?In this podcast, Hira Mian discusses the relationship between age and

How is the immune reconstitution in patients who stop therapy after achieving MRD negativity?

Feb 9th, 2023 3m 10s

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Timothy Schmidt, University of Wisconsin-Madison, Madison, US. We asked, How is the immune reconstitution in pa

What are the main discrepancies between MM treating centers in Brazil?

Feb 6th, 2023 2m 49s

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paulo, BR. We asked, What are the main discrepancies

What are the initial data of dara-CyBorD in patients with extramedullary disease?

Feb 3rd, 2023 4m 55s

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Meral Beksac, Ankara University, Ankara, TR. We asked, What are the initial data of dara-CyBorD in patients wit

Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?

Oct 2nd, 2022 3m 3s

During the 19th International Myeloma Society Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Roman Hájek, University of Ostrava, Ostrava, CZ. We asked, Which patients might benefit the most from isatuximab-based combinations i

Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM

Aug 5th, 2022 9m 13s

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, María‑Victoria Mateos chaired a recorded discussion that also featured Nina Shah, Paul Richardson, Morie Gertz, and Heinz Ludwig. The topic of this discussion wa

The role of consolidation after autologous stem cell transplantation

Aug 5th, 2022 12m 37s

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, Morie Gertz chaired a recorded discussion that also featured María-Victoria Mateos, Nina Shah, Paul Richardson, and Elena Zamagni. The topic of this discussion w

What are the pros and cons of bispecific antibodies for multiple myeloma?

Jul 25th, 2022 27m 57s

During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J. Jakubowiak, The University of Chicago, Chicago, US. We asked, What are the pros and cons of bispecific

Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM

Apr 21st, 2022 9m 5s

During the 3rd European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, How can bispecific antibodies be combined with monoclonal anti

Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?

Jan 14th, 2022 13m 24s

During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Jacob Laubach, Dana-Farber Cancer Institute, Boston, US, and Peter Voorhees, Levine Cancer Institute, Charlotte, US. We asked, Daratumumab as ma

Managing infections with novel immunotherapies: Prevention, treatment, and impact on the QoL of patients with MM

Nov 9th, 2021 8m 50s

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Michel Delforge, UCLouvain, Louvain-la-Neuve, BE and Noopur Raje, Massachusetts General Hospital, Boston, US. In this podcast, they discuss the topic: Managing

Should 'cure' be the goal for multiple myeloma?

Oct 14th, 2021 28m 9s

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma?This podcast captures the roundtable discussion with Mohama

Treating elderly and frail patients with MM: Cure versus disease control

Oct 7th, 2021 13m 54s

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Vincent Rajkumar, Mayo Clinic, Rochester, US, discussed: T

Is transplantation still relevant? If yes, in what context?

Sep 30th, 2021 13m 41s

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Sagar Lonial, Winship Cancer Institute of Emory University

The challenges of monitoring organ response in AL amyloidosis: What has been achieved so far?

Sep 24th, 2021 19m 49s

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Eli Muchtar, Mayo Clinic, Rochester, US and Suzanne Lentzsch, Columbia University, New York, US. We asked, The challenges of monitoring organ response in AL amy

Is the treatment of high-risk SMM the way for achieving the cure?

Sep 23rd, 2021 13m 5s

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? María-Victoria Mateos, University Hospital of Salamanca, S

Does 'cure' have a different meaning in MM?

Sep 15th, 2021 15m 15s

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne Universi

How to treat first relapse in lenalidomide-refractory MM?

Jul 19th, 2021 15m 5s

During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Clifton C. Mo and Omar Nadeem, Dana-Farber Cancer Institute, Boston, US. We asked, How to treat first relapse in lenalidomide-refractory multiple myeloma (MM)?In this podc

With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk MM?

Jun 30th, 2021 5m 9s

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk

With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk MM?

Jun 30th, 2021 5m 9s

When BCMA-directed therapy is not an option, how should we treat late relapse?

May 24th, 2021 3m 9s

During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Xavier Leleu, Poitiers University Hospital, Poitiers, FR. We asked, When BCMA-directed therapy is not a

When BCMA-directed therapy is not an option, how should we treat late relapse?

May 24th, 2021 3m 9s

What do you need to remember when facing CAR T-cell toxicities?

Apr 12th, 2021 11m 5s

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Professor Philip McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What do you need to remember when facing CAR T-cell toxicities? In this po